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7Increased nuclear suppressor of cytokine signaling 1
in asthmatic bronchial epithelium suppresses rhinovirus
induction of innate interferons
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Heidelberg, Germany, and Parkville, AustraliaBackground: Rhinovirus infections are the dominant cause of
asthma exacerbations, and deficient virus induction of IFN-a/b/
l in asthmatic patients is important in asthma exacerbation
pathogenesis. Mechanisms causing this interferon deficiency in
asthmatic patients are unknown.
Objective: We sought to investigate the expression of suppressor
of cytokine signaling (SOCS) 1 in tissues from asthmatic
patients and its possible role in impaired virus-induced
interferon induction in these patients.
Methods: We assessed SOCS1mRNA and protein levels in vitro,
bronchial biopsy specimens, and mice. The role of SOCS1 was
inferred by proof-of-concept studies using overexpression with
reporter genes andSOCS1-deficientmice. Anuclear role of SOCS1
was shown by using bronchial biopsy staining, overexpression of
mutant SOCS1 constructs, and confocal microscopy. SOCS1 levels
were also correlated with asthma-related clinical outcomes.
Results: We report induction of SOCS1 in bronchial epithelial
cells (BECs) by asthma exacerbation–related cytokines and by
rhinovirus infection in vitro. We found that SOCS1 was
increased in vivo in bronchial epithelium and related to asthma
severity. SOCS1 expression was also increased in primary BECs
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epithelium, mouse lung macrophages, and SOCS1-deficient
mice, SOCS1 suppressed rhinovirus induction of interferons.
Suppression of virus-induced interferon levels was dependent on
SOCS1 nuclear translocation but independent of proteasomal
degradation of transcription factors. Nuclear SOCS1 levels were
also increased in BECs from asthmatic patients.
Conclusion: We describe a novel mechanism explaining
interferon deficiency in asthmatic patients through a novel
nuclear function of SOCS1 and identify SOCS1 as an important
therapeutic target for asthma exacerbations. (J Allergy Clin
Immunol 2015;nnn:nnn-nnn.)
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Asthma exacerbations are the major cause of morbidity,
mortality, and health care costs in asthmatic patients and cause
a decrease in lung function.1 Respiratory tract virus infections, of
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2 GIELEN ET ALAbbreviations usedAA: Atopic asthmaBAL: Bronchoalveolar lavageBEC: Bronchial epithelial cellCISH: Cytokine-inducible SH2-containing proteinGFP: Green fluorescent proteinISG: Interferon-stimulated geneISRE: Interferon-stimulated response elementKC: Keratinocyte-derived chemokineLIX: LPS-induced CXC chemokineNANA: Nonatopic nonasthmaticNF-kB: Nuclear factor kBNLS: Nuclear localization sequencepolyI:C: Polyinosinic-polycytidylic acidSOCS: Suppressor of cytokine signalingSOCS1wt: Full-length wild-type human SOCS1STAT: Signal transducer and activator of transcriptionSTRA: Severe therapy-resistant atopic asthmathe great majority of asthma exacerbations. The mechanisms
involved in asthma exacerbations are poorly understood, but
increased susceptibility to rhinovirus infections is strongly
implicated.4,5
We originally reported impaired induction of the innate antiviral
IFN-b6 and IFN-l7 by rhinovirus infection in lung cells from asth-
matic patients and implicated deficiency of IFN-l in asthma exac-
erbation severity in human subjects in vivo.7 Recent studies have
confirmed deficient respiratory tract virus induction of IFN-a,
IFN-b, and/or IFN-l in bronchial epithelial cells (BECs), bron-
choalveolar lavage (BAL)macrophages, peripheral blood dendritic
cells, and PBMCs from asthmatic patients.8-14 Although impaired
interferon induction might be associated with asthma control,15
the mechanism or mechanisms responsible for impaired interferon
induction are currently unknown. Two recent studies reported that
exogenous TGF-b enhanced rhinovirus replication in fibroblasts
and BECs and that this was accompanied by reduced interferon
levels.16,17 The latter study also reported that anti–TGF-b treatment
of BECs from asthmatic patients was accompanied by reduced
suppressor of cytokine signaling (SOCS) 1 and SOCS3gene expres-
sion,17 possibly associating these SOCS proteins with interferon
deficiency, but no investigations of SOCS functionwere performed.
There are 7 SOCS family members in human subjects
and mice: SOCS1 through SOCS6 and cytokine-inducible
SH2-containing protein (CISH). The family is characterized by
a central SH2 domain and a C-terminal SOCS box motif that
couples SOCS proteins to a Cullin-RING E3 ubiquitin ligase
complex. Therefore SOCS proteins can act as adaptors to target
bound proteins for ubiquitination and proteasomal degradation
and thus function as negative regulators of cytokine signaling.
SOCS1 through SOCS3 have been studied in detail, including
development of knockout mice.18-20 SOCS1 deletion causes
fatal inflammation, which can be rescued by deletion of
IFNG.18 In mice SOCS1 and SOCS2 negatively regulate TH2
immunity19,21-23; however, a human polymorphism enhancing
SOCS1 expression is associated with asthma.24 T-cell SOCS3
mRNA levels are increased in asthmatic patients and correlate
with IgE levels,20 but a functional role for SOCS3 in human
asthma is unknown, and thus the role of SOCS proteins in asthma
is unclear.In the context of viral infections, SOCS proteins suppress
cytokine receptor signaling through inhibition of Janus-activated
kinase and signal transducer and activator of transcription (STAT)
signaling,25-27 and preliminary data suggest that SOCS1 and
SOCS3 might suppress influenza-induced IFN-b promoter
activation.28 However, there are no data on the possible role of
SOCS proteins in suppressing viral induction of interferons in
patients with asthma and during asthma exacerbations.
We hypothesized that SOCS1/3 would be induced by
proinflammatory cytokines and rhinovirus infection in BECs
in vitro. Thus we investigated SOCS expression in human primary
BECs from asthmatic patients ex vivo and their possible role in
interferon deficiency and increased viral replication in these cells.
We also investigated whether SOCS1/3 proteins could directly
suppress viral induction of innate interferons in airway cells
in vitro and in vivo. We found that SOCS1, but not SOCS3, levels
were increased in cells from asthmatic patients and also found that
nuclear localization of SOCS1 was required for suppression of
virus-induced interferons. This suppression was independent of
the only known nuclear function of SOCS1, which is induction
of proteasomal degradation of signaling proteins. Thus we
describe a novel mechanism explaining interferon deficiency in
asthmatic patients, a new nuclear function of SOCS1, and
identify SOCS1 as an important therapeutic target for asthma
exacerbations.
METHODS
For detailed methods, including patient data, animal models, reagents,
experimental protocols, and statistical analysis, please see the Methods
section and Tables E1-E3 in this article’s Online Repository at www.
jacionline.org.RESULTS
SOCS1 is induced in primary BECs by
proinflammatory cytokines and rhinovirus
SOCS3 mRNA expression is increased in T cells in asthmatic
patients,20 but upregulation of SOCS1 by IL-13 in airway smooth
muscle cells from asthmatic patients is impaired.22 Thus whether
SOCS proteins are upregulated in asthmatic patients is uncertain,
and whether SOCS proteins are upregulated in cells that are
infected by respiratory tract viruses is unknown. Therefore we
first investigated the effects of the TH2 cytokines IL-4 and
IL-13 on SOCS1 through SOCS6 and CISH mRNA and protein
expression in BECs because these cytokines are strongly
implicated in asthma pathogenesis.29,30 IL-4 and IL-13 both
induced SOCS1 mRNA and protein expression (Fig 1, A).
Densitometric analysis for the Western blots in Fig 1 are shown
in Fig E1 in this article’s Online Repository at www.jacionline.
org. No other SOCS proteins/mRNAs were induced by IL-4 or
IL-13, with the exception of CISH, which was significantly
induced by both.
We next investigated the ability of the proinflammatory
cytokines TNF-a and IL-1b, rhinovirus infection, and
polyinosinic-polycytidylic acid (polyI:C; as a mimic of other
viral infections) to induce SOCS expression in BECs. We found
that TNF-a and IL-1b both induced SOCS1 (Fig 1, B) but not any
other SOCS family member, whereas both SOCS1 (Fig 1, C) and
SOCS3 (see Fig E2 in this article’s Online Repository at www.
jacionline.org) were induced by RV1B (representative of minor
group rhinoviruses), RV16 (major group), and polyI:C. RV1B
FIG 1. SOCS1 mRNA and protein were induced in primary BECs by viruses and cytokines important in
asthma pathogenesis. A, The TH2 cytokines IL-4 and IL-13 both induced SOCS1 mRNA and protein in a
time-dependent manner. B, The proinflammatory cytokines TNF-a and IL-1b also induced SOCS1 mRNA
and protein in a time-dependent manner. C, RV1B, RV16, and 1 mg/mL polyI:C all induced SOCS1 mRNA
and protein in a time-dependent manner. *P < .05 versus medium-treated cells.
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CISH in BECs. The induction of SOCS1 by RV1B and RV16
was susceptible to UV irradiation and through filtering out virus
with a 30-kDa molecular weight filter and was dose dependent
(see Fig E1). These data indicate that SOCS1 is induced by
proinflammatory cytokines and rhinovirus infection in primary
human BECs.SOCS1 protein expression is increased in bronchial
epithelium from asthmatic adults
We next investigated the abundance of SOCS1 and SOCS3
proteins in biopsy specimens of adults with uninfected mild-to-
moderate atopic asthma (AA) compared with nonatopic
nonasthmatic (NANA) adult control donors. SOCS1, but not
SOCS3, staining intensity was significantly increased in the
FIG 2. SOCS1 protein levels were increased in bronchial biopsy specimens from adults with mild-to-
moderate AA compared with those seen in NANA adults and correlated with asthma-related clinical
outcomes. A, Representative pictures showing epithelial staining of SOCS1 (left panels) and SOCS3 (right
panels). Bar 5 10-mm scale (340 objective was used in all pictures). Patients with AA showed significantly
more SOCS1, but not SOCS3, staining compared with that seen in NANA subjects. *P < .05, bar represents
median. ns, Not significant. B, SOCS1 bronchial biopsy scores positively correlated with the number of
positive skin pick test responses (SPTs) and negatively correlated with the dose of histamine causing a
20% reduction in lung function (PC20).
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in healthy NANA subjects (Fig 2, A). There was a positive
correlation between SOCS1 staining scores and numbers of
positive skin prick test responses, with a similar nonsignificant
trend for IgE levels (data not shown) and a negative correlation
with the provocative concentration of histamine causing a 20%
reduction in lung function (PC20 histamine), indicating greater
intensity of SOCS1 staining was related to greater severity of
atopy and airway hyperresponsiveness (Fig 2, B). In contrast,
SOCS3 biopsy staining scores did not significantly correlate
with any clinical outcome. SOC1 protein expression did not
correlate with numbers of exacerbations (data not shown).
SOCS1 completely suppressed interferon promoter
activation in BECs
Having established that SOCS1 levels are increased in patients
with AA and related to airway hyperresponsiveness to histamine,
the ability of SOCS1 to modulate rhinovirus induction of
interferons in BECs in vitro was examined. We focused our
attention on induction of IFN-b and IFN-ls because these are
the interferon subtypes induced by viral infection of BECs.31
Because total interferon induction is a consequence of both direct
viral induction of interferon and subsequent paracrine interferon
induction of interferon, we investigated both viral and interferon
induction of the IFN-b and IFN-l1 promoters, as well as
interferon induction of promoters of interferon-responsive genes.
We found that overexpression of SOCS1 in both primary
human BECs and in the human BEC cell line BEAS-2B (see
Fig E3 in this article’s Online Repository at www.jacionline.org)
completely inhibited exogenous IFN-b–induced activation ofboth the IFN-b and IFN-l1 promoters. In BEAS-2B cells
SOCS1 also suppressed interferon induction of a minimal
promoter containing the interferon-stimulated response
element (ISRE) and a minimal promoter containing a STAT1/2-
responsive element (see Fig E3), which are type I interferon–
responsive promoters induced by the interferon-stimulated
gene factor 3 and STAT1/2 transcription factor complexes,
respectively, and are typical readouts for interferon signaling.
Overexpression of SOCS1 also completely suppressed
rhinovirus-induced IFN-b and IFN-l1 promoter activation in
primary human BECs (Fig 3, A). In contrast, overexpression of
SOCS1 in BEAS-2B cells significantly increased rhinovirus-,
IL-1b–, and TNF-a–induced CXCL8 promoter activation
(around 20- to 25-fold; see Fig E4 in this article’s Online
Repository at www.jacionline.org).Augmented IFN-b expression in BAL macrophages
from SOCS1-deficient mice
To determine whether the converse were true, namely whether
the absence of SOCS1 would lead to augmentation of interferon
induction, we used ex vivo–cultured BAL macrophages from
SOCS12/2IFN-g2/2mice and control IFN-g2/2mice and found
that in the absence of SOCS1, IFN-b mRNA induction by
rhinovirus at 4 and 8 hours was significantly increased
compared with that seen in IFN-g2/2 control mice (Fig 3, B).
This enhancement was specific to interferon induction because
BAL macrophages from SOCS12/2IFN-g2/2 mice and
IFN-g2/2 mice showed no difference in induction of TNF-a
mRNA by rhinovirus (Fig 3, B).
FIG 3. SOCS1 suppressed rhinovirus-induced interferon induction but not rhinovirus-induced
proinflammatory cytokine induction. A, SOCS1-transfected cells showed completely suppressed
RV1B-induced IFN-b and IFN-l1 promoter activation versus pORF empty vector control at 24 hours.
***P < .001. B, RV1B-induced IFN-bmRNA expression was increased in ex vivo–cultured BAL macrophages
from SOCS12/2 IFN-g2/2mice compared with IFN-g2/2mice. No differenceswere observed between these 2
groups for RV1B-induced TNF-amRNA. *P < .05. C, RV1B-induced IFN-a expression (8 hours after infection)
was significantly increased inRV1B-infectedSOCS12/2IFN-g2/2mice comparedwith IFN-g2/2mice. BAL IFN-
l (24 hours) levels showed a nonsignificant trend for increase in RV1B-infected SOCS12/2IFN-g2/2 mice,
whereas CCL5 levels (24 hours) were also significantly increased in RV1B-infected SOCS12/2IFN-g2/2mice
compared with IFN-g2/2 mice. CXCL1/KC and LIX/CXCL5 (both 48 hours) were both decreased in
BAL fluid from RV1B-infected SOCS12/2IFN-g2/2 mice compared with IFN-g2/2 mice. A mixture
of SOCS12/2IFN-g2/2 and IFN-g2/2 mice was used for the UV-RV1B and UV-RV1B plus IL-13 groups.
*P < .05 and ***P < .001. ns, Not significant.
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FIG 4. SOCS1, but not SOCS3, mRNA expression was increased in primary BECs from children with severe
asthma compared with that seen in control children and was related to impaired interferon induction and
increased viral release. A, SOCS1 mRNA levels were increased at baseline in children with STRA compared
with NANA subjects. No differences between NANA subjects and children with STRA were observed for
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in vivo
We next investigated the importance of SOCS1 in regulating
rhinovirus-induced interferon in vivo using IFN-g2/2 and
SOCS12/2IFN-g2/2 mice. Mice were pretreated with IL-13 for
8 hours to enhance SOCS1 levels before rhinovirus infection
(see Fig E5, A, in this article’s Online Repository at www.
jacionline.org). IL-13 pretreatment significantly enhanced
SOCS1 mRNA expression in the lungs of IFN-g2/2 mice by
approximately 3-fold (see Fig E5, B). As expected, there was
no SOCS1 expression in SOCS1-deficient mice. On rhinovirus
infection, IL-13–pretreated IFN-g2/2 mice in which SOCS1
was induced had significantly deficient IFN-a, trends toward
deficient IFN-l, and significantly deficient RANTES/CCL5 (an
interferon-inducible chemokine) in BAL fluid when compared
with IL-13–pretreated SOCS12/2IFN-g2/2 mice, in which
SOCS1 could not be induced (Fig 3, C). Consistent with our
observation that enhanced SOCS1 expression substantially
enhanced rhinovirus induction of the CXCL8 promoter in human
BECs in vitro (see Fig E4, A), enhanced SOCS1 expression signi-
ficantly augmented rhinovirus induction of the mouse CXCL8
homologues keratinocyte-derived chemokine (KC)/CXCL1 and
LPS-induced CXC chemokine (LIX)/CXCL5 in vivo (Fig 3, C).Increased SOCS1 levels in BECs from asthmatic
children were associated with interferon deficiency
BECs from children with STRA with confirmed rhinovirus-
induced interferon deficiency14 were used to investigate whether
SOCS1 levels are increased in primary BECs from patients with
severe asthma. We also sought to establish whether there were
relationships between SOCS1 levels, interferon deficiency, and
viral replication. SOCS1, but not SOCS3, mRNA expression
levels were increased (approximately 8- to 9-fold) in
unstimulated and uninfected primary human BECs from children
with severe asthma compared with those in BECs from NANA
control subjects (Fig 4, A). SOCS1 mRNA levels in the
unstimulated and uninfected cells were significantly inversely
correlated with IFN-l1 and IFN-l2/3 mRNA induction by
polyI:C, with a similar but nonsignificant trend for IFN-b
(Fig 4, B) and, importantly, with induction of all 3 interferon sub-
types by RV16 (Fig 4, C). However, RV1B showed no significant
correlation (Fig 4, D). Baseline SOCS1 mRNA levels correlated
positively with RV1B release at 48 hours after infection in
BECs but did not correlate with RV16 release (Fig 4, E).SOCS1 suppression of interferons required SOCS1
nuclear translocation
SOCS1 can prevent nuclear factor kB (NF-kB) signaling by
entering the nucleus through a C-terminal proximal nuclear
localization sequence (NLS) and targeting NF-kB p65 for
proteasomal degradation through the C-terminal SOCS box.32SOCS3mRNA levels. *P < .05. ns, Not significant. B, Pol
8 hours after treatment negatively correlated with basel
l2/3 mRNA levels 24 hours after infection negative
D, RV1B-induced IFN-b/l1/l2/3 mRNA levels 24 hours
correlation with baseline SOCS1 mRNA levels. E, R
as measured by means of titration in HeLa cells, positiTherefore we hypothesized that SOCS1 might suppress
rhinovirus-induced interferon induction by translocating
into the nucleus and initiating proteasomal degradation of
transcription factors required for interferon induction. To
investigate the role of nuclear translocation of SOCS1 and of
the SOCS box, we used vectors expressing green fluorescent
protein (GFP)–tagged full-length wild-type human SOCS1
(SOCS1wt) and 2 mutants. The mutants included SOCS1
truncations with both the NLS and the SOCS box deleted
(Q108X) or with a deleted SOCS box alone, leaving the NLS
intact (R172X; Fig 5, A).32 We found that the SOCS1 mutant
that lacked the NLS (Q108X) was indeed unable to translocate
to the nucleus; however, both SOCS1wt and R172X, which had
a deleted SOCS box but intact NLS, were able to translocate to
the nucleus (Fig 5, A). We then tested the ability of these
constructs to suppress rhinovirus induction of interferons in
BEAS-2B cells and found that the construct lacking the NLS
(Q108X) had lost its ability to suppress rhinovirus-induced
IFN-b and IFN-l promoter activation, whereas fully intact
SOCS1 (SOCS1wt containing both the NLS and the SOCS box)
and R172X (containing the NLS but lacking the SOCS box)
were still suppressive (Fig 5, B). Furthermore, SOCS1wt, but
neither Q108X nor R172X, suppressed interferon-induced
ISRE promoter activation. This definitively proves that
SOCS1-mediated suppression of rhinovirus-induced interferon
is NLS dependent but SOCS box independent and therefore
distinct from interferon-induced ISRE activation, which is
dependent on both the NLS and the SOCS box (Fig 5, B).
Furthermore, the requirement for nuclear localization for both
rhinovirus- and interferon-induced responses was supported
with a full-length SOCS1 construct containing mutated NLS
residues (D6RA), which was impaired in its ability to enter
the nucleus and exhibited a less suppressive effect on
interferon induction when compared with SOCS1wt (see
Fig E6, B-D, in this article’s Online Repository at
www.jacionline.org). SOCS1wt, R172X, and Q108X proteins
were expressed at similar levels, as determined by using Western
blotting (see Fig E6, A).
Because the construct (R172X) lacking the SOCS box (which
is required for initiation of proteasomal degradation) still
suppressed rhinovirus-induced interferon promoter activation
(Fig 5, B), this suggested that SOCS1-mediated suppression of
rhinovirus-induced interferon was independent of proteasomal
degradation. Therefore we next investigated whether pretreat-
ment with the 28S proteasome inhibitor MG132 would be able
to prevent SOCS1-mediated inhibition of rhinovirus-induced
interferon. At a concentration of 1 mmol/L, MG132 significantly
suppressed rhinovirus-induced NF-kB promoter activation,
which is dependent on proteasomal degradation of IkB and
therefore sensitive to this inhibitor (Fig 5, C). We found that
neither the 1 mmol/L dose nor the 2 mmol/L dose had any effect
on SOCS1-mediated suppression of rhinovirus-induced IFN-b
or IFN-l promoter activation, confirming that proteasomalyI:C induced IFN-b, IFN-l1, and IFNl2/3mRNA levels
ine SOCS1 mRNA levels. C, RV16-induced IFN-b/l1/
ly correlated with baseline SOCS1 mRNA levels.
after infection showed trends toward a negative
V16 and RV1B release 48 hours after infection,
vely correlated with baseline SOCS1 mRNA levels.
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rhinovirus-induced interferon induction (Fig 5, D).
Finally, to determine whether nuclear SOCS1 levels were
increased in asthmatic patients, we re-evaluated protein staining
for SOCS1 in bronchial biopsy specimens from patients with
mild-to-moderate AA and nonatopic healthy subjects and
specifically assessed only nuclear staining. Nuclear SOCS1
staining was clearly observed in the BEC layer in these biopsy
specimens, with significantly higher levels of SOCS1 nuclear
staining in patients with AA compared with healthy subjects
(Fig 5, E). Furthermore, numbers of nuclear SOCS1-positive cells
positively correlated with serum total IgE levels in these subjects.
Nuclear SOCS1 levels did not correlate with exacerbation
numbers (data not shown).DISCUSSION
Impaired interferon induction in response to rhinovirus and
other viral infections ex vivo has been reported recently and in
several studies is related to markers of underlying asthma
severity.6,7,11,13,33 Furthermore, trends toward a higher viral
load in asthmatic patients compared with that seen in healthy
control subjects have been observed in vivo.5 The mechanism or
mechanisms responsible for this impaired induction of interferon
are unknown. Herewe describe increased expression of SOCS1 in
asthmatic patients, the importance of its nuclear rather than
cytoplasmic function, and its role in deficient interferon
induction. These data together identify avenues to inhibit the
expression or function of SOCS1 as potential therapies for
asthma exacerbations, boosting deficient interferon responses
and potentially suppressing harmful inflammatory chemokine
induction.
Previous studies of SOCS1 expression in asthmatic patients
have led to contradictory findings.22,24 The induction and role of
SOCS1 in airway epithelium has been poorly studied to date, with
a single study reporting increased SOCS1 mRNA expression in
response to IFN-g stimulation of primary BECs.34 We found
that a number of stimuli increased SOCS1 mRNA expression,
including TH2 and proinflammatory cytokine levels, rhinovirus,
and polyI:C. Uninfected (stable) patients with AA had increased
SOCS1 protein staining in bronchial biopsy specimens compared
with nonasthmatic subjects, which we argue was likely a result ofFIG 5. SOCS1-mediated suppression of rhinovirus-
translocation but not proteasome-mediated degrad
localization of SOCS1wt and the R172X mutant, whe
localization. All images used the 360 objective. Bar 5
dihydrochloride. B, SOCS1wt and R172X both suppre
whereas Q108X did not. SOCS1wt, but neither Q108
ISRE-responsive promoter activation. *P < .05 and *
vector–transfected, RV1B-infected, or IFN-b–treated g
rhinovirus-infected or IFN-b–treated cells. ns, Not si
RV1B-infected, or IFN-b–treated cells; lower ns, not s
cells). C, MG132 inhibited RV1B-induced NF-kB act
RV1B-infected untreated group. D, MG132 had
rhinovirus-induced IFN-l1 or IFN-b promoter activation
the pORF-transfected RV1B-infected untreated gro
pORF-transfected RV1B-infected group treated with 2
the pORF-transfected RV1B-infected group treated wit
pORF-transfected RV1B-infected untreated group. E, I
observed in patients with AA compared with that see
correlated with IgE levels in these subjects. All images u
SOCS1 staining. Bar 5 10-mm scale. *P < .05.ongoing allergic airways inflammation. The observed increased
expression in patients with stable asthmawouldmean that onviral
infection, the ability to respond with rapid interferon induction
would be impaired. This is entirely in keeping with the
delayed and quantitatively impaired early interferon induction
reported in studies identifying interferon deficiency in asthmatic
patients.6,13,14
We further found that SOCS1 expression was induced by
exacerbation-related and virus-induced proinflammatory
cytokines, polyI:C, and rhinovirus infection of BECs. This
strongly supports the idea that SOCS1 expression is likely to be
further upregulated as asthma exacerbations progress, which is
consistent with observations of substantially impaired interferon
responses and greater viral replication in lung cells at later time
points,6,7,13,14 increased duration of rhinovirus-related lower
airways symptoms in asthmatic patients,4 and strong relationships
between impaired interferon induction and asthma exacerbation
severity in vivo.7
In cell lines SOCS1 can suppress interferon induction by
influenza viruses.28 In the present study we only investigated
SOCS1 expression and the role of SOCS1 in rhinovirus infection.
Although rhinovirus is the main trigger of asthma exacerbations,
other viruses can cause asthma exacerbations, and whether this is
in part due to impaired antiviral immunity in lung epithelial cells
remains unclear. Therefore we cannot claim that the role of
SOCS1 in suppressing virus-induced interferon levels is limited
to rhinovirus infection. It would be of interest to the field to
examine the role of SOCS1 in other respiratory tract virus
infections; of interest, impaired interferon induction has been
observed in PBMCs and dendritic cells from patients with
respiratory syncytial virus and influenza, respectively.8,9
Recently, Spann et al35 showed higher viral loads in respiratory
syncytial virus– and metapneumovirus-infected tracheal
epithelial cells from wheezy children, but no impairments in
type or type III interferons were observed.35 Clearly, more studies
are required to determine whether impaired interferon induction
is mostly associated with rhinovirus infection and whether
SOCS1 can impair interferon induction by other respiratory tract
viruses in primary BEC ex vivo models. Therefore our data
potentially explain why interferon is impaired in asthmatic pa-
tients but does not explain why rhinovirus is the most frequent
cause of asthma exacerbations.induced interferon expression required nuclear
ation. A, Confocal microscopy showed nuclear
reas the Q108X mutant showed only cytoplasmic
10-mm scale. DAPI, 49-6-Diamidino-2-phenylindole
ssed RV1B-induced interferon promoter activation,
X nor R172X, suppressed IFN-b–induced minimal
**P < .001, as indicated and versus GFP empty
roup. 111P < .001 versus SOCS1wt-transfected
gnificant (upper ns, not significant vs SOCS1wt,
ignificant vs GFP, RV1B-infected, or IFN-b–treated
ivation. **P < .01 and ***P < .001 versus the
no effect on SOCS1-mediated suppression of
. *P < .05 and ***P < .001, as indicated and versus
up. 1P < .05 and 111P < .001 versus the
mmol/L MG132. 3P < .05 and 333P < .001 versus
h 1 mmol/L MG132. ns, Not significant versus the
ncreased nuclear SOCS1 expression in BECs was
n in NANA subjects, and nuclear SOCS1 staining
sed the360 objective. Black arrows indicate nuclear
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markers of asthma (PC20) and also numbers of positive skin prick
test responses, suggesting a relationship between SOCS1
expression and AA. At this point, we cannot definitively conclude
whether SOCS1 expression is increased because of asthma, atopy,
or both. Furthermore, because our study numbers remain small,
there is a need for further studies with larger patient numbers to
confirm whether SOCS1 expression is related to clinical markers
of asthma or atopy. We speculated that bronchial epithelial
SOCS1 expressionmight be increased because of ongoing airway
inflammation, and our findings that SOCS1 expression was
induced by TH2 and non-TH2 cytokines support this hypothesis.
Because the non-TH2 cytokines TNF-a and IL-1b also induced
SOCS1, this is unlikely to be a strictly TH2-dependent process.
However, the link between SOCS1 and TH2 responses has been
previously established. SOCS1 is a negative regulator of TH2
responses.21,23 SOCS1 has a known role in hematopoietic cells.
Increased SOCS1 levels in hematopoietic cells act to counter
excessive TH2 outgrowth, whereby in BECs excessive TH2
cytokine signaling might also induce SOCS1, but our results
suggest this likely hampers epithelium-derived innate interferon
induction and immunity to viruses. Indeed, we found that
bronchial epithelial SOCS1 expression correlated with the
number of positive skin prick test responses and airway
hyperresponsiveness but not exacerbation numbers, suggesting
that SOCS1 can be increased in response to but not limited to
allergic inflammation. In support, Baraldo et al11 have shown a
clear association between impaired rhinovirus-induced interferon
induction in asthmatic patients and increased TH2 cytokine
expression in the bronchial mucosa. The antagonistic effects of
interferons on TH2 signaling and the allergic cascade and vice
versa is also underscored by other studies.9,12,36-39 Further studies
are required to see whether impaired interferon induction
is consistent with other markers of non-TH2 inflammation.
Therefore we argue that therapies reducing TH2, TNF, or IL-1b
signaling could enhance antiviral immunity in asthmatic patients.
The latter hypothesis is supported by the observed therapeutic
effect in selected populations that anti-TH2 therapies have
recently been shown to have on asthma exacerbations.29,30,40
Although clinical studies investigating the effects of anti–IL-1b
therapies are yet to be performed, the effects of TNF therapy on
asthma exacerbation rates have been reported by just one study.41
Anti-TNF therapy (etanercept) had no effect versus placebo on
the asthma exacerbation rate; however, this rate was extremely
low across both groups (n 5 1 each), and therefore no definitive
conclusion can be reached. Considering the findings in this
article, the effects of anti–IL-1b and anti-TNF therapy on
interferon responses and asthma exacerbation rates and severity
are warranted and would be of interest.
We found that SOCS1 suppressed virus-induced interferon
induction but augmented IL-8/CXCL8 in vitro and augmented
KC/CXCL1 and LIX/CXCL5 in mice in vivo. Having excess
SOCS1 in BECs could be doubly deleterious in patients with
asthma exacerbations in that beneficial antiviral pathways
mediated by interferons are suppressed and harmful pro-
inflammatory responses are augmented. These data clearly point
to approaches that will inhibit the expression or function of
SOCS1 as novel strategies for therapeutic intervention in patients
with asthma exacerbations.
We found that SOCS1 was a potent suppressor of virus-
induced type I and type III interferon induction. We originallyattempted to grow tracheal epithelial cells from SOCS12/2
mice but found these difficult to grow with established
protocols. This omission is an unfortunate limitation of our
study. We then opted to use BAL macrophages from
SOCS12/2 mice and found that SOCS12/2 mice had enhanced
interferon induction on rhinovirus infection compared with
wild-type mice, enforcing the idea that SOCS1 is a negative
regulator of virus-induced interferon. Consistent with the
literature in other systems,25,26 we also found that SOCS1
regulated interferon-induced signaling in BECs. IFN-a/b/ls
can all act as interferon-stimulated genes (ISGs), being induced
by IFN-b and thus providing a positive feedback loop,42,43 and
we observed that SOCS1 inhibited IFN-b–induced IFN-b and
IFN-l1 promoter activation. SOCS1-mediated inhibition of
interferon receptor signaling has been shown to be dependent
on the SOCS box.26,44 The SOCS box deletant R172X, which
could undergo nuclear translocation, profoundly inhibited
rhinovirus-induced IFN-b and IFN-l promoter activation but
not that of an ISRE-containing promoter, which is dependent
on interferon receptor signaling, therefore proving that this
SOCS1 mutant suppresses virus-induced rather than
interferon-induced interferon induction. These data are
consistent with the known requirement for the SOCS box in
SOCS-mediated suppression of interferon receptor signaling.
In contrast, SOCS1 suppression of rhinovirus-induced
interferon induction was independent of the SOCS box and did
not require proteasomal degradation. SOCS1-mediated
suppression of rhinovirus-induced interferon induction was very
clearly dependent on nuclear localization because the SOCS1
construct unable to localize to the nucleus (Q108X) was unable to
suppress rhinovirus-induced interferon promoter activation, and
another construct with the NLS mutated (D6RA) also
demonstrated a significantly less suppressive effect than
SOCS1wt. Importantly, and supporting the specific role for
nuclear expression of SOCS1, we were able to show that
bronchial epithelial expression of nuclear SOCS1 was
significantly increased in asthmatic patients. Further studies
will be required to understand the specific mechanism of how
nuclear SOCS1 suppresses virus-induced interferon induction.
Our present studies clearly identify suppression of virus-induced
interferon induction as a novel function of nuclear SOCS1 and,
independent of its previous known nuclear function, SOCS box
mediated proteasomal degradation.
In summary, our data provide novel findings relating to the
requirement of nuclear SOCS1 to exert novel effects of
suppression of virus-induced interferon induction. The data
further demonstrate nuclear SOCS1 plays an important role in
regulation of interferon deficiency in patients with AA,
providing a mechanistic explanation for this important phe-
nomenon. Because SOCS1 inhibits both virus- and interferon-
induced interferon induction through distinct mechanisms, this
makes inhibition of SOCS1 an attractive therapeutic target
capable of restoring deficient interferon responses. The
ability of SOCS1 to enhance proinflammatory responses adds
further attractiveness to SOCS1 as a therapeutic target. Thus
these studies provide evidence for SOCS1 as a novel
therapeutic target for asthma exacerbations, a major unmet
medical need.We thank Mellisa Dixon and Tom Burgoyne for technical support.
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d Increased SOCS1 levels in cells from asthmatic patients
impair interferon induction in asthmatic patients through
its nuclear localization. However, SOCS1 did not impair
virus-induced inflammatory mediators, showing speci-
ficity for antiviral immunity.
d This represents a novel mechanism explaining interferon
deficiency in asthmatic patients, shows a new nuclear
function of SOCS1, and identifies SOCS1 as an important
therapeutic target for asthma exacerbations.REFERENCES
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METHODS
Viruses, cells, and reagents
Rhinovirus serotypes 16 and 1B were grown in Ohio HeLa cells and UV
inactivated, as previously described.E1 In some experiments RV1B and RV16
were filtered bymean of centrifugation (at 12,000 rpm for 5minutes) through a
filter with a 30-kDa molecular weight cutoff (Amicon, Dublin, Ireland), thus
producing a virus-free filtrate. RV1B used for in vivo purposes was
concentrated and purified, as previously described.E2 BEAS-2B cells were
maintained in RPMI 1640 medium with 10% FCS. Primary BECs (Clonetics,
Wokingham, United Kingdom) from nonsmoking nonasthmatic donors were
grown according to the manufacturer’s recommended protocol. PolyI:C
(Sigma-Aldrich, Dorset, United Kingdom) was made up at 1 mg/mL in water
and stored at 2808C. Recombinant mouse IL-13 and recombinant human
IL-4, IL-13, TNF-a, and IL-1b (R&D Systems, Abingdon, United Kingdom)
were made up in sterile PBS containing 0.1% BSA and stored at 2808C.
SOCS1-pORF and pORF control vector were purchased from InvivoGen
(Nottingham, United Kingdom). The wild-type SOCS1-GFP, GFP empty
vector, and SOCS1-GFP tagged mutants R172X, Q108X, and D6RA were
used, as previously described.E3 The 2125-bp fragment of the human
IFN-b promoter in pGL3 was a kind gift from T. Fujita, and the IFN-l1
promoter was made by cutting the 1kB human IFN-l1 promoterE4 and
subcloning into vector pGL3 (Promega, Madison, Wis). The minimal
ISRE-containing promoters were purchased from Clontech (Saint-Germain-
en-Laye, France). The minimal STAT1/2-containing promoter was purchased
from Panomics (Vignate-Milano, Italy). All plasmids were grown in
Escherichia coli, plasmid purified with Maxiprep (Qiagen, Crawley, United
Kingdom), and stored in water at 1 mg/mL at 2808C.
Patients with mild-to-moderate AA and NANA
subjects
Bronchial biopsy specimens were obtained at bronchoscopy from a recent
clinical study performed in our laboratory, which reported deficient
rhinovirus-induced IFN-a/b responses in BAL cells from adults with AA
compared with nonatopic healthy control adult subjects.E5 Inclusion and
exclusion criteria have been reported.E5 Numbers of exacerbations in the
last year were reported, as previously described.E5 Table E1 provides the clini-
cal characteristics of the participants providing bronchial biopsy specimens
for analysis in this study. All subjects provided written informed consent,
and ethics approval for this study was given by St Mary’s NHS Trust Research
Ethics Committee (08/H0712/39 and 07/Q0403/20, Professor S. L. Johnston).
BEC culture from children with STRA and NANA
donors
BECs were obtained through bronchoscopies performed on 11 pediatric
patients with STRA, as previously described.E6 NANA control children were
recruited through the Royal Brompton Hospital and Children’s Hospital in
Bern, Switzerland. The control children (n 5 11) had no personal or family
history of asthma and no record of food allergy, rhinitis, or eczema. Use of
bronchial brushings from patients with severe asthma and control children
was approved by both the Royal Brompton NHS Trust (02/302, Professor
A. Bush) and the Ethics Committee for the Canton of Bern and University
Children’s Hospital Bern, Switzerland (77/09, A/Professor N. Regamey).
BECswere grown from bronchial brushings in bronchial epithelial cell growth
medium, as previously described.E6 Table E2 provides the clinical
characteristics of the participants in the severe asthma study.
Animal models
IFN-g2/2 and SOCS12/2IFN-g2/2 mice on a C57BL/6 background were
bred and used, as previously described.E7 All breeding and experimentation
was performed according to regulations outlined by the Home Office UK.
The mice were lightly anesthetized with isoflurane and treated and infected
intranasally. Mice were treated with 0.5 mg of recombinant mouse IL-13
(R&D Systems) 8 hours before challenge with a 5 3 106 median tissue
culture infectious dose of RV1B, as previously described.E2 IFN-g2/2 and
IFN-g2/2SOCS12/2 C57BL/6 mouse BAL macrophages were harvested by
means of lavage and placed in RPMI medium with 10% FCS before plating
Treatment of cells and infection with rhinovirus
BEAS-2B cells, primary human BECs (Clonetics), and primary BECs
obtained from asthmatic and nonasthmatic donors were infectedwith RV1B o
RV16 (multiplicity of infection5 1). BECs (Clonetics) were treated with IL-4
and IL-13 at 50 ng/mL and IL-1b and TNF-a at 10 ng/mL (R&D Systems) o
polyI:C diluted in BEBMmediumand used at 1mg/mL for various time points
Mouse BAL macrophages were counted, plated at 13 106 cells per well, and
infected with RV1B as above and harvested at the indicated time points.
Transfection of human BECs with plasmid DNA and
reporter assays
Confluent monolayers of BEAS-2B cells and primary human BECs in
12-well plates (Nunc, Rochester, NY) were transiently transfected with
plasmid DNA and luciferase measured by using the Dual lucerifase assay
(Promega), as previously described.E8
SOCS1 immunohistochemistry
SOCS1- and SOCS3-positive cells were detected by using the EnVision
Peroxidase stainingmethod. After dewaxing, the sections were incubated with
peroxidase-blocking solution and probed with primary rabbit anti-SOCS1
(catalog no. 18-003-43725; GenWay Biotech, San Diego, Calif) and rabbi
anti-SOCS3 (catalog no. E16854; Spring Bioscience, Pleasanton, Calif
overnight at 48C. The sections were then incubated with EnVision goa
anti-rabbit antibody for 30 minutes (K4003; DAKO, Glostrup, Denmark)
After washing, sections were incubated with chromogen (liquid diaminoben
zidine and peroxide buffer). Slides were counterstained with hematoxylin to
provide nuclear and morphologic detail and mounted. Irrelevant rabbit IgG
(Sigma-Aldrich) was used for the primary layer as a negative contro
procedure. The slides were blinded, and the immunostaining intensity fo
total SOCS1 and SOCS3 in the airway epithelium was semiquantitatively
scored as 0 to 3 (05 negative, 15 weak staining, 25moderate staining, and
3 5 strong staining). The SOCS1 and SOCS3 nuclear staining of epithelia
cells was counted from 2 to 3 bronchial biopsy specimens per subject, and the
averagewas used for statistical analyses. The data for epithelial nuclear counts
were expressed as the number of positive nuclei per 0.1 mm2 of epithelium.
Confocal microscopy
BEAS-2B cells were seeded into transwell plates (Nunc) and transfected
with GFP-tagged SOCS1 plasmids. After 24 hours, cells were fixed in 4%
paraformaldehyde and counterstained with Evans Blue (red for both
cytoplasm and nuclear) and 49-6-diamidino-2-phenylindole dihydrochloride
(blue for nuclear). The cells were observed at room temperature, and images
were captured with a Zeiss LSM 510 inverted confocal microscope with LSM
510 software (Zeiss, Oberkochen, Germany).
RNA isolation, cDNA synthesis, and TaqMan
real-time PCR
Total RNA isolation, cDNA synthesis, and TaqMan PCR were performed
as previously described.E6 All data are presented as the copy number per 1mL
Primer and probe sequences are presented in Table E3.
SDS-PAGE and Western blotting
Total protein lysates were run on 16%Tris glycine polyacrylamide gels and
transferred onto nitrocellulose membranes (Invitrogen, Paisley, United
Kingdom), blocked in 5% skimmed milk, and probed with antibodies specific
for human SOCS1 at 500 ng/mL (Millipore, Temecula, Calif) and human
SOCS3 at 200 ng/mL (Santa Cruz Biotechnology, Santa Cruz, Calif)
GFP-tagged SOCS1 proteins were analyzed by means of Western
blotting with anti-GFP (Abcam, Cambridge, United Kingdom) at 1 mg/mL
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Anti–a-tubulin (1 mg/mL, Santa Cruz Biotechnology) was used to detect
a-tubulin as a load control. The secondary antibody used was goat anti-mouse
horseradish peroxidase at 0.08 mg/mL (Santa Cruz Biotechnology). Blots
were developed with ECL (GE Healthcare, Fairfield, Conn).
ELISA
ELISAs for mouse IFN-a, IFN-l, KC/CXCL1, RANTES/CCL5, and
LIX/CXCL5 were from R&D Systems and used according to the
manufacturer’s recommended protocol.
Statistical analysis
Nonclinical data are represented as means6 SEMs. At least 4 experiments
were performed for in vitro and ex vivo experiments. For in vivo experiments, 3
experiments were performed with 4 to 7 mice per group. Time-course data in
BECs and mice were analyzed by using 2-way ANOVA at a 95% CI with the
Bonferroni multiple comparison test. Reporter assay and ex vivo BAL
macrophage data were analyzed by using 1-way ANOVA at a 95% CI if
significant, and differences were pinpointed with the Bonferroni multiple
comparison test. Clinical data are represented as medians and were analyzed
by using theMann-WhitneyU test. Correlations in clinical data were analyzed
by using the Spearman test. A P value of less than .05 was considered
statistically different.
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FIG E1. Densitometry of SOCS1Western blots in Fig 1, effects of SOCS1mRNA induction by rhinovirus after
UV inactivation and filtration, and dose-dependent induction of SOCS1 mRNA by rhinovirus. A-C, Primary
human BECs were treated with IL-4 or IL-13 (Fig E1, A) or TNF-a or IL-1b (Fig E1, B) or were infected with
RV1B, RV16, or polyI:C (1 mg/mL; Fig E1, C), and total protein was harvested over time and plotted versus
a-tubulin as a control protein (n5 1 experiment for all induced SOCS1 protein). D and E, BECs were infected
with RV16 (Fig E1, D), UV-inactivated RV16, or filtered RV16, or RV1B (Fig E1, E). F-RVIB, Filtered RV1B; UV-
RV1B, UV-inactivated RV1B. UV-inactivated and rhinovirus-filtered (virus-free) preparations both showed a
reduction in SOCS1 mRNA expression. F and G, BECs infected with RV16 (Fig E1, F) or RV1B (Fig E1, G)
showed dose-dependent inductions of SOCS1 mRNA. *P < .05, **P < .01, and ***P < .001, as indicated
or versus rhinovirus treatment, by means of 1-way ANOVA. ns, Not significant. There were 3 to 4
experiments from BECs derived from 3 to 4 healthy control donors.
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FIG E2. SOCS3 mRNA and protein were induced in BECs by rhinovirus and polyI:C. Primary human BECs
were infected with RV1B, RV16, or polyI:C (1 mg/mL), and total RNA and total protein were harvested over
time. RV1B (A), RV16 (B), and polyI:C (C) all induced SOCS3mRNA and protein in a time-dependent manner.
Values are presented as means 6 SEMs (n 5 4 experiments). **P < .01 versus medium treatment, 2-way
ANOVA.
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=FIG E4. SOCS1 overexpression increased RV1B-, IL-1b– and TNF-a–induced CXCL8 promoter activation.
BEAS-2B cells were seeded and transfected with SOCS1 or the empty vector control pORF and infected
with RV1B or treated with 10 ng/mL IL-1b or TNF-a. SOCS1 overexpression increased RV1B-induced
(A), IL-1b–induced (B), and TNF-a–induced (C) CXCL8 promoter activation at 24 hours. Values are presented
as means6 SEMs (n5 4 experiments). *P < .05 and ***P < .001, 1-way ANOVAwith the Bonferroni multiple
comparison test. ns, Not significant.
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activation of minimal promoters containing ISRE and STAT1/2 binding sites. Human BECs were transfected
with plasmids encoding SOCS1 or empty vector pORF. A and B, IFN-b (5 ng/mL) induced IFN-b promoter
activation (Fig E3, A) and IFN-l1 promoter activation (Fig E3, B) at 24 hours, which were both significantly
suppressed by SOCS1 (n5 4 experiments). BEAS-2B cells were transfected with plasmids encoding SOCS1
or empty vector pORF. SOCS1 also inhibited both IFN-b (5 ng/mL)–induced IFN-b promoter activation
(Fig E3, C) and IFN-l1 promoter activation (Fig E3, D) at 24 hours. E and F, SOCS1 also inhibited
IFN-b–induced ISRE-driven promoter activation (Fig E3, E) and STAT1/2-driven promoter activation
(Fig E3, F) at 24 hours. Values are presented as means 6 SEMs (n 5 3 experiments). *P < .05, **P < .01,
and ***P < .001, as indicated, by using 1-way ANOVA with the Bonferroni multiple comparison test.
FIG E5. IL-13 treatment increased lung SOCS1 expression. IFN-g2/2 C57Bl/6
mice were treated with 0.5 mg of IL-13 or PBS (vehicle) through the
intranasal (i.n.) route. A, Schematic diagram showing the timing of
IL-13/PBS treatment and RV1B/UV-RV1B infection 8 hours later. BAL and
lung mRNA was harvested at 8, 24, and 48 hours after infection. B, IL-13
treatment induced SOCS1 mRNA in IFN-g2/2 mice at 4 hours after IL-13
treatment compared with PBS-treated mice. Values are presented as
means 6 SEMs (n 5 4 animals per group). **P < .01, t test.
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FIG E6. Mutation of the SOCS1 NLS resulted in reduced suppression of rhinovirus-induced interferon
promoter and IFN-b–induced minimal ISRE responsive promoter activation compared with SOCS1wt. A, All
SOCS1 mutants expressed equally as assessed by anti-GFP detection when compared with anti–a-tubulin
using Western blotting (WB). UT, Untransfected. B, The SOCS1 NLS mutant D6RA showed predominately
cytoplasmic localization by using confocal microscopy. Left panel, GFP; right panel, 49-6-Diamidino-2-
phenylindole dihydrochloride. Evans blue and GFP overlay: bar 5 10-mm scale. A diagram of SOCS1wt
and the NLS mutant D6RA shows the 6 mutated amino acid residues in the NLS region. C, D6RA showed
less suppression compared with SOCS1wt of RV1B-induced IFN-l1. D, RV1B-induced IFN-b promoter
activation. E, IFN-b (5 ng/mL) induced ISRE minimal promoter activation at 24 hours (n 5 4 independent
experiments). *P < .05, **P < .01, and ***P < .01, as indicated and versus RV1B-infected or IFN-b–treated
GFP-transfected cells. 111P < .001 versus SOCS1wt-transfected, RV1B-infected, or IFN-b–treated cells by
using 1-way ANOVA with the Bonferroni multiple comparison test. ns, Not significant (upper ns vs
SOCS1wt, RV1B-infected, or IFN-b–treated cells; lower ns vs GFP, RV1B-infected, or IFN-b–treated cells).
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TABLE E1. Clinical characteristics of NANA healthy control
adults and adults with mild-to-moderate AA used for
bronchial biopsies
Clinical characteristics NANA subjects Patients with AA P value
No. 14 17 NA
Sex 43% M/57% F 76% M/24% F
Age (y) 40 (24-55) 34 (21-51) .6196
ACQ score 0 0.6 (0-3) NA
ICS (% of patients) 0 71 NA
ICS and LABA
(% of patients)
0 53 NA
Exacerbations/year 0 1 (1-4) NA
Oral steroid courses/year (n) 0 0 (0-1) NA
PEF (% predicted) 99 (85-123) 91 (66-123) .1901
FEV1 (% predicted) 95 (80-107) 89 (56-133) .4625
FEV1/FVC ratio (%) 88 (78-95) 76 (67-91) .0002
PC20 histamine (mg/mL) >_16 (NA) 1 (0-4) .0002
Total serum IgE (U/mL) 9.5 (2-64) 127.0 (23-970) <.0001
SPT (no. of positive
responses)
0 (0-0) 4 (1-6) NA
Values are presented as medians (ranges), except for sex, ICS, and ICS plus LABA.
Statistical differences were calculated by using the Mann-Whitney U test.
ACQ, Asthma control questionnaire; F, female; FVC, forced vital capacity; ICS,
inhaled corticosteroids; LABA, long-acting b2-agonists; M, male; NA, not applicable;
PEF, peak expiratory flow; SPT, skin prick test.
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TABLE E2. Clinical characteristics of NANA control children
and atopic children with STRA used for cultured BECs
Clinical characteristics
NANA
subjects
Children
with STRA P value
No. 11 11
Sex 64% M/36% F 55% M/45% F 1.00
Age (y) 7 (2-15) 11 (9-15) .11
Family history of atopy No Yes NA
Total serum IgE (U/mL) NA 374 (121-4610) NA
No. of positive RAST results NA 3 (0-6) NA
Cumulative RAST score NA 60.4 (0.03-195) NA
Family history of asthma No Yes NA
Physician’s diagnosis
of asthma
No Yes NA
FEV1 (% predicted) NA 79 (36-108) NA
FVC (% predicted) NA 80.6 (19-111) NA
Values are presented as medians (ranges), except for sex. RASTs include house dust
mite, mixed grass pollen, dog, cat, egg white, peanut, mixed tree pollen, Aspergillus
fumigatus, Alternaria species, Cladosporium herbarum, and cockroach. The Mann-
Whitney U test was used to determine significant differences between the 2 groups.
The cumulative RAST score is defined as the total sum of positive RAST scores for
each allergen. One hundred percent of children with STRA reported a family history
of atopy and asthma and had a physician’s diagnosis of asthma. These data were
previously reported by Edwards et al.E6
F, Female; FVC, forced vital capacity; M, male; NA, not applicable.
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TABLE E3. TaqMan real-time RT-PCR primers and probes used
for quantitative PCR
Name Sequence (59-39)
hIFN-b forward (300 nmol/L) cgccgcattgaccatcta
hIFN-b reverse (900 nmol/L) ttagccaggaggttctcaacaatagtgtca
hIFN-b probe
(FAM 59-TAMRA 39 [100 nmol/L])
tcagacaacattcatctagcactggctgga
hIFN-l1/IL-29 forward (300 nmol/L) ggacgccttggaagagtcact
hIFN-l1/IL-29 reverse (900 nmol/L) agaagcctcaggtcccaattc
hIFN-l1/IL-29 probe
(FAM 59-TAMRA 39 [100 nmol/L])
agttgcagctctcctgtcttccccg
hIFN-l2/3/IL-28AB forward (300 nmol/L) ctgccacatagcccagttca
hIFN-l2/3/IL-28AB reverse (900 nmol/L) agaagcgactcttctaaggcatctt
hIFN-l2/3 probe
(FAM 59-TAMRA 39 [100 nmol/L])
tctccacaggagctgcaggccttta
hSOCS1 forward (900 nmol/L) ccctggttgttgtagcagctt
hSOCS1 reverse (900 nmol/L) ggtttgtgcaaagatactgggtatat
hSOCS1 probe
(FAM 59-TAMRA 39 [100 nmol/L])
aggtaggaggtgcgagttcaggtcctg
hSOCS3 forward (900 nmol/L) tgggacgatagcaaccacaa
hSOCS3 reverse (900 nmol/L) cgaagtgtcccctgtttgga
hSOCS3 probe
(FAM 59-TAMRA 39 [100 nmol/L])
tggattctccttcaattcctcagcttccc
mSOCS1 forward (900 nmol/L) ccgtgggtcgcgagaac
mSOCS1 reverse (900 nmol/L) aaggaactcaggtagtcacggagta
mSOCS1 probe
(FAM 59-TAMRA 39 [100 nmol/L])
tggcgcgcatccctcttaaccc
mIFN-b forward (900 nmol/L) ctccacgctgcgttcctgctgtg
mIFN-b reverse (900 nmol/L) aaaggattgccacattgctc
mIFN-b probe
(FAM 59-TAMRA 39 [100 nmol/L])
tcaagcagcctcttctcgat
mTNF-a forward (900M) agcctgtagcccacgtcgta
mTNF-a reverse (900M) ttgagatccatgccgttgg
mTNF-a probe
(FAM 59-TAMRA 39 [100 nmol/L])
aaccaccaagtggaggagcagctgg
18S forward (300 nmol/L) cgccgctagaggtgaaattct
18S reverse (300 nmol/L) cattcttggcaaatgctttcg
18S probe
(FAM 59-TAMRA 39 [100 nmol/L])
accggcgcaagacggaccaga
h, Human; m, mouse.
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